Detalhe da pesquisa
1.
Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange.
Blood
; 2024 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38838300
2.
Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis.
Blood
; 143(11): 1006-1017, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142424
3.
BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
Am J Hematol
; 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38822666
4.
Emicizumab for the treatment of acquired hemophilia A.
Blood
; 137(3): 410-419, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32766881
5.
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis.
Blood
; 137(2): 238-247, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32777817
6.
Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis.
Blood
; 137(15): 2070-2084, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512435
7.
N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.
Am J Hematol
; 98(2): 290-299, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588398
8.
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Int J Mol Sci
; 24(20)2023 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37894806
9.
Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms.
Am J Hematol
; 96(6): 719-726, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33784434
10.
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Allergy
; 75(8): 1927-1938, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108361
11.
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.
Int J Mol Sci
; 20(12)2019 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31216696
12.
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.
Int J Mol Sci
; 20(17)2019 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31470642
13.
Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.
Haematologica
; 103(11): 1760-1771, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29976735
14.
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Haematologica
; 103(5): 799-809, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439183
15.
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Haematologica
; 102(9): 1519-1529, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28596283
16.
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Am J Hematol
; 92(10): E567-E574, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28699225
17.
Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
J Clin Apher
; 32(4): 224-234, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27578390
18.
CD52 is a molecular target in advanced systemic mastocytosis.
FASEB J
; 28(8): 3540-51, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24760752
19.
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Nat Chem Biol
; 8(11): 905-912, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23023260
20.
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.
Blood Adv
; 8(11): 2890-2900, 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38593217